SCHEMBL30134835

SCHEMBL30134835

CC(C)(C)CC(NC(=O)OC(C)(C)C)C(=O)Nc1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 2/20 0.52
CTSK P43235 2/20 0.52
AAK1 Q2M2I8 2/20 0.52
HDAC8 Q9BY41 2/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 2/20 0.47
EGFR P00533 1/20 0.46
MAPK1 P28482 2/20 0.45
TSHR P16473 1/20 0.45
FPR2 P25090 3/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA9 Q16790 1/20 0.44
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135004 1.00 CTSS (0.52) CTSSCTSKAAK1HDAC8MEN1
SCHEMBL30134945 0.86 AAK1 (0.69) CTSSCTSKAAK1MEN1KMT2A
SCHEMBL30135112 0.84 CA12 (0.48) CTSSCTSKAAK1HDAC8MEN1
SCHEMBL30134897 0.83 HDAC8 (0.66) CTSSCTSKHDAC8MEN1KMT2A
SCHEMBL28773022 0.83 HDAC8 (0.66) CTSSCTSKHDAC8MEN1KMT2A
SCHEMBL30134871 0.83 HDAC8 (0.66) CTSSCTSKHDAC8MEN1KMT2A
SCHEMBL25160116 0.81 AAK1 (0.43) CTSSCTSKAAK1HDAC8MEN1
SCHEMBL1752662 0.81 MEN1 (0.51) CTSSCTSKAAK1MEN1KMT2A
SCHEMBL30135039 0.81 CTSS (0.63) CTSSCTSKAAK1HDAC8MEN1
SCHEMBL30134989 0.81 HDAC4 (0.47) AAK1HDAC8EGFRCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 US disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK CTSS 3694/4885CTSK 851/4885AAK1 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.